ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SIM0609

A development code. Also written as “SIM0609 for injection”, “dose expansion of SIM0609 in CRC” and “dose expansion of SIM0609 in GC/GEJC cohort”.

Its studies are led by Simcere Pharmaceutical Group.

Furthest: phase 1, since Nov 20, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group11 open or runningphase 1since Nov 20, 2025Nov 20, 2025Dec 2028phase 1 · NCT07265921

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2025First study: phase 1 study in Advanced Solid CancerFirst studyNCT07265921 · 232 planned · China

Ahead

  1. Dec 2028Primary completion: phase 1 study in Advanced Solid CancerNCT07265921

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265921Advanced Solid Cancer · China1RecruitingDec 2028232

How it is read

Names in the registry

  • “SIM0609 for injection”, 1 entry
  • “dose expansion of SIM0609 in CRC”, 1 entry
  • “dose expansion of SIM0609 in GC/GEJC cohort”, 1 entry
  • “dose expansion of SIM0609 in PDAC cohort”, 1 entry
  • “dose expansion of SIM0609 in positive other solid tumors”, 1 entry

Codes read as this program: SIM0609.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.